These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 30178500)

  • 21. Role of protein S in castration-resistant prostate cancer-like cells.
    Ning P; Zhong JG; Jiang F; Zhang Y; Zhao J; Tian F; Li W
    Endocr Relat Cancer; 2016 Aug; 23(8):595-607. PubMed ID: 27342144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
    Zeng J; Liu W; Fan YZ; He DL; Li L
    Theranostics; 2018; 8(1):109-123. PubMed ID: 29290796
    [No Abstract]   [Full Text] [Related]  

  • 23. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
    Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
    Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3.
    Hu F; Zhao Y; Yu Y; Fang JM; Cui R; Liu ZQ; Guo XL; Xu Q
    Cancer Lett; 2018 Mar; 416():24-30. PubMed ID: 29246644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Knocking down SOX2 overcomes the resistance of prostate cancer to castration via notch signaling.
    Du Z; Chen X; Zhu P; Lv Q; Yong J; Gu J
    Mol Biol Rep; 2023 Nov; 50(11):9007-9017. PubMed ID: 37716921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells.
    Ueda K; Kawashima H; Ohtani S; Deng WG; Ravoori M; Bankson J; Gao B; Girard L; Minna JD; Roth JA; Kundra V; Ji L
    Cancer Res; 2006 Oct; 66(19):9682-90. PubMed ID: 17018626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
    Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
    Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. β-elemonic acid inhibits growth and triggers apoptosis in human castration-resistant prostate cancer cells through the suppression of JAK2/STAT3/MCL-1 and NF-ĸB signal pathways.
    Bao X; Zhu J; Ren C; Zhao A; Zhang M; Zhu Z; Lu X; Zhang Y; Li X; Sima X; Li J; Zhang Q; Ma B
    Chem Biol Interact; 2021 Jun; 342():109477. PubMed ID: 33878321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ACSL4 promotes prostate cancer growth, invasion and hormonal resistance.
    Wu X; Deng F; Li Y; Daniels G; Du X; Ren Q; Wang J; Wang LH; Yang Y; Zhang V; Zhang D; Ye F; Melamed J; Monaco ME; Lee P
    Oncotarget; 2015 Dec; 6(42):44849-63. PubMed ID: 26636648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
    Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
    Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer.
    Zhou X; Zou L; Chen W; Yang T; Luo J; Wu K; Shu F; Tan X; Yang Y; Cen S; Li C; Mao X
    Pharmacol Res; 2021 Feb; 164():105305. PubMed ID: 33197601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy.
    Lin JZ; Wang WW; Hu TT; Zhu GY; Li LN; Zhang CY; Xu Z; Yu HB; Wu HF; Zhu JG
    Cancer Lett; 2020 Jan; 469():481-489. PubMed ID: 31738958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclohexanone curcumin analogs inhibit the progression of castration-resistant prostate cancer in vitro and in vivo.
    Mapoung S; Suzuki S; Fuji S; Naiki-Ito A; Kato H; Yodkeeree S; Ovatlarnporn C; Takahashi S; Limtrakul Dejkriengkraikul P
    Cancer Sci; 2019 Feb; 110(2):596-607. PubMed ID: 30499149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer.
    Hongo H; Kosaka T; Oya M
    Cancer Sci; 2018 Sep; 109(9):2937-2945. PubMed ID: 29989268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upregulated KDM4B promotes prostate cancer cell proliferation by activating autophagy.
    Sha J; Han Q; Chi C; Zhu Y; Pan J; Dong B; Huang Y; Xia W; Xue W
    J Cell Physiol; 2020 Mar; 235(3):2129-2138. PubMed ID: 31468537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
    Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C
    Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Novel Salicylanilide Derivative Induces Autophagy Cell Death in Castration-Resistant Prostate Cancer via ER Stress-Activated PERK Signaling Pathway.
    Hsieh CL; Huang HS; Chen KC; Saka T; Chiang CY; Chung LWK; Sung SY
    Mol Cancer Ther; 2020 Jan; 19(1):101-111. PubMed ID: 31530650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
    Gao S; Ye H; Gerrin S; Wang H; Sharma A; Chen S; Patnaik A; Sowalsky AG; Voznesensky O; Han W; Yu Z; Mostaghel EA; Nelson PS; Taplin ME; Balk SP; Cai C
    Clin Cancer Res; 2016 Jul; 22(14):3672-82. PubMed ID: 26936914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
    Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.